Holen Sie sich die Stockscreener-App
28.15
2.09%
-0.60
Vorhandelsmarkt:
26.21
-1.94
-6.89%
Schlusskurs vom Vortag:
$28.75
Offen:
$28.82
24-Stunden-Volumen:
404.40K
Relative Volume:
1.02
Marktkapitalisierung:
$788.41M
Einnahmen:
$219.79M
Nettoeinkommen (Verlust:
$-57.47M
KGV:
-13.09
EPS:
-2.15
Netto-Cashflow:
$-19.25M
1W Leistung:
+4.03%
1M Leistung:
-1.61%
6M Leistung:
+26.35%
1J Leistung:
+20.25%
1-Tages-Spanne:
$27.65
$28.87
1-Wochen-Bereich:
$26.70
$28.90
52-Wochen-Spanne:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Vergleichen Sie CSTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
28.15 | 788.41M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
580.57 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
215.01 | 154.61B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.04 | 41.95B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
465.03 | 38.08B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
200.04 | 36.31B | 15.32B | 1.41B | 1.96B | 7.62 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Tritonpoint Wealth LLC - MarketBeat
Should You Bet on Castle Biosciences? The Truth Behind Its Stock Struggles! - Jomfruland.net
Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Vanguard Group Inc. Increases Stake in Castle Biosciences Inc. - GuruFocus.com
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet - Yahoo Finance
Leerink Partnrs Issues Optimistic Forecast for CSTL Earnings - Defense World
JPMorgan Chase & Co. Raises Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
JPMorgan Chase & Co. Has $1.98 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
FY2024 Earnings Estimate for CSTL Issued By Leerink Partnrs - Defense World
Castle Biosciences (NASDAQ:CSTL) Trading 8.1% HigherTime to Buy? - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Buy" by Brokerages - MarketBeat
Castle Biosciences' DecisionDx-SCC Shows 92% Accuracy in Groundbreaking 1,400-Patient Cancer Study - StockTitan
Despite shrinking by US$214m in the past week, Castle Biosciences (NASDAQ:CSTL) shareholders are still up 29% over 1 year - Simply Wall St
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock - Investing.com India
Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $71,902 in stock By Investing.com - Investing.com Australia
Castle Biosciences stock tumbles following guidance concerns - Investing.com India
Castle Biosciences stock tumbles following guidance concerns By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Trading Down 14%What's Next? - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Expects 50% Revenue Growth in 2024, Hits Record 96,000 Tests Despite Medicare Setback - StockTitan
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results - Milton Daily Standard
Harbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences stock falls following Medicare coverage denial By Investing.com - Investing.com Canada
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownHere's Why - MarketBeat
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 Shares - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 Shares - MarketBeat
Castle Biosciences' chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Canada
Castle Biosciences’ chief commercial officer sells $66,900 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences director Bradbury sells shares worth $229,225 By Investing.com - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells shares worth $228,066 - Investing.com India
Castle Biosciences director Bradbury sells shares worth $229,225 - Investing.com
Castle Biosciences' chief commercial officer sells $66,900 in shares - Investing.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Up 6.2%Here's Why - MarketBeat
Castle Biosciences gains NY approval for esophageal test By Investing.com - Investing.com Nigeria
Castle Biosciences gains New York state approval for Barrett’s oesophagus test - Yahoo Finance
Castle Biosciences gains NY approval for esophageal test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test - Business Wire
Castle Biosciences (NASDAQ:CSTL) Given Overweight Rating at Stephens - Defense World
Castle Biosciences (NASDAQ:CSTL) Earns Overweight Rating from Stephens - MarketBeat
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock - Benzinga
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.26%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):